咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Disitamab vedotin combined wit... 收藏

Disitamab vedotin combined with apatinib in gastric cancer: A case report and review of literature

作     者:Xiao-Qian Li Jing Yang Bo Liu Shu-Mei Han 

作者机构:Department of Medical OncologyShandong Cancer Hospital and InstituteShandong First Medical University and Shandong Academy of Medical SciencesJinan 510000Shandong ProvinceChina 

出 版 物:《World Journal of Clinical Oncology》 (世界临床肿瘤学杂志(英文版))

年 卷 期:2024年第15卷第10期

页      面:1351-1358页

学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主  题:Human epidermal growth factor receptor 2-positive gastric cancer RC48 Apatinib Combination therapy Progression-free survival Case report 

摘      要:BACKGROUND In patients with human epidermal growth factor receptor 2(HER2)-overex-pressing gastric cancer(GC),the combination of HER2 targeting and a standard first-line chemotherapy regimen has been demonstrated to significantly improve their ***,in a proportion of patients,cancer progresses within a short period of time,and there is currently no standard treatment after disease *** SUMMARY This study presents a case of a 51-year-old male with advanced GC who un-derwent radical resection(Billroth type II subtotal gastrectomy and gastrojejun-ostomy)and resection of liver *** staining revealed a HER2 score of 2+,a dMMR status,and a Ki67 proliferation index of 30%to 40%.The gene test results indicated the presence of ERBB2 amplification and a PD-L1 expression level of less than 5%.Since December 2021,the patient has experienced disease progression during both first-line(two cycles of KN026 combined with KN046)and second-line(five cycles of nivolumab combined with trastuzumab and SOX chemotherapy)treatment *** patient s prognosis following the first and second lines of treatment was unfavorable,with pro-gression occurring in a relatively short *** third-line therapy,disitamab vedotin(RC48)plus apatinib was *** the time of this report,the patient had achieved a progression-free survival(PFS)of 25.8 months,which exceeded the median survival time for patients with advanced *** Despite the unfavorable prognosis associated with advanced GC,the imple-mentation of personalized treatment approaches may still prove beneficial for select *** patients with HER2-positive GC with extensive metastatic involvement,the use of the HER2-targeted combination with apatinib has demonstrated the potential to prolong both PFS and overall survival.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分